Introduction {#Sec1}
============

Metastatic dissemination is an important prognostic factor for patients with gastro-intestinal cancer. Exact staging is crucial to determine appropriate multimodal therapeutic strategies. The current staging method for gastric cancer (GC) is based on the staging system of the International Union against cancer Tumor-Node-Metastasis (TNM), in which the degree of tumor penetration (pT) and nodal status (pN) are the two main prognostic indicators. Early stage patients are considered for surgery. However, approximately 50 % of GC patients suffer from tumor relapses even after radical surgery (Marrelli et al. [@CR15]).

Many research groups have focused on the identification of new potential biomarkers and novel tests, yet their specificity and sensitivity in a clinical setting frequently go reported. Recently, in advanced GC, measurement of HER2-expression is being recommended when selecting patients for treatment with Trastuzumab (Duffy et al. [@CR5]). Circulating Tumor Cells (CTCs) and disseminated tumor cells (DTCs) could be rare events of primary tumor progression, which could be used for identification of cancer recurrence or progression risk. The methodology for CTC-detection in gastrointestinal cancer has been recently reviewed elsewhere (Kin et al. [@CR12]). The development of new isolation platforms for CTCs is well supported by the need for new predictive markers in clinical treatment.

The real number of CTCs analyzed in peripheral blood (PB) in gastrointestinal cancer (colorectal cancer, GC, oesophageal cancer) is low compared with other malignancies such a breast and prostate cancer. The absolute (median) numbers in metastatic colorectal carcinoma (mCRC) are reported as 1--2 CTCs/7.5 mL of blood in mCRC, 3--5 CTCs/7.5 mL of blood in metastatic prostate cancer, and 6--7 CTCs/7.5 mL of blood in metastatic breast cancer (Negin and Cohen [@CR19]; Hiraiwa et al. [@CR10]; Moreno et al. [@CR18]; Cristofanilli et al. [@CR4]).

Follow-up studies in GC patients suggest that CTC-positive cases with an increased burden of CTCs were associated with a poorer prognosis than CTC-negative patients, and the situation was similar for DTCs (Wang et al. [@CR25]). Both localized and metastatic GC can shed a detectable concentration of CTCs into the blood. The presence of CTCs in the circulation indicates a high risk of tumor recurrence as well as unfavourable clinical outcomes, even for early GC (Zhang and Ge [@CR27]).

The prognostic use of CTCs in GC has been reported in several studies (Arigami et al. [@CR3]; Saad et al. [@CR20]; Pituch-Noworolska et al. [@CR1]; Yeh et al. [@CR26]; Koga et al. [@CR13]; Illert et al. [@CR11]; Uen et al. [@CR23]). For GC, the presence of CTC and tumor markers (e.g. EpCAM/CK8/CK18/C19) seems prognostically the most relevant (Hiraiwa et al. [@CR10]; Matsusaka et al. [@CR16]). Based on the data analyzed, detection of CTCs may provide a useful non-invasive method for prognosis, as well as a means of confirming a GC diagnosis.

We have developed an easy and highly sensitive methodology for detecting CTCs in GC patients, namely the MetaCell^®^ platform. In this study we demonstrate its use for enrichment, separation and cultivation of CTCs.

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

To date, 22 patients with diagnosed GC have been enrolled in the study. All patients had GC localized within 5 cm of the gastro-oesophageal junction, and were candidates for surgery. The patients' details are shown in Table [1](#Tab1){ref-type="table"}.Table 1Patients characteristics (22 patients in total, median age 68,75 years)T stagePatients (N)CTC positive (N)%T13133.3T211100T38562.5T410550*N stage*N03133.3N18337.5N26466.67N35480*M stage*M0171058.8M15240*Disease stage*I3133.3II4250III10770IV5240

Peripheral blood was collected prior to surgery. For each patient approximately 8 mL of venous blood was drawn from the antecubital veins and placed into S-Monovette tubes (Sarstedt AG & Co., Nümbrecht, Germany) containing 1.6 mg EDTA/ml blood as an anticoagulant. The samples were processed at room temperature using an isolation procedure completed within 24 h of the blood draw.

The ethics committees of all participating universities and hospitals approved the study protocol according to the Declaration of Helsinki. All patients also provided written consent.

CTC enrichment and culture {#Sec4}
--------------------------

A new size-based separation method for viable CTC-enrichment from unclotted Peripheral blood (PB) was recently introduced (MetaCell^®^, MetaCell s.r.o., Ostrava, Czech Republic). The process is based on the filtration of PB through porous polycarbonate membrane (pores of 8 μm diameter, MetaCell s.r.o., Ostrava, Czech Republic). Successive blood transfer into the filtration tube in several steps is preferred, to prevent blood clotting on the membrane filter. The PB filter flow is supported naturally by capillary action of the absorbent material touching the membrane filter. Afterwards, the membrane filter, which is kept in a plastic ring, is transferred into the 6-well cultivation plate; RPMI medium (Sigma-Aldrich, Munich, Germany) is added to the filter top and CTCs are cultured on the membrane in vitro, under standard cancer cell culture conditions (37 °C and 5 % atmospheric CO~2~, ) and observed by inverted microscope. Alternatively, viable CTCs may be observed under a fluorescence microscope applying vital nuclear stain (NucBlue™, Life Technologies, Bleiswijk, Netherlands) and/or vital cytoplasmic stain (Celltracker™, Life Technologies, Bleiswijk, Netherlands). The CTCs are grown in an FBS (Sigma-Aldrich, Germany) enriched RPMI medium (10 %) for a minimum of 14 days and are analyzed by means of histochemistry (May-Grünwald staining (Bio-Optica, Milan, Italy) and immunohistochemistry using the tumor specific antibodies to determine the cell origin (mouse monoclonal anti-cytokeratin peptide 18-FITC antibody (Sigma), DAPI (Sigma), Prolong Gold Antifade Reagent (Life Technologies, Carlsbad, CA, USA).

Next, the enriched CTC fraction can be transferred from the membrane and cultured directly on a plastic surface or microscope slide. Microscope slide culturing is preferred if immunohistochemistry/immunofluorescence analysis is planned. If an intermediate CTCs-analysis is needed, the CTC-fraction is transferred in PBS (1.5 mL) to the cytospin slide. The slide is then dried for 24 h and analyzed by immunohistochemistry.

Additionally, to confirm the origin of the cells on the separation membrane, the CTC-gene expression analysis was performed in parallel with the immunohistochemistry. The cell fraction enriched on the membrane without in vitro culturing was assigned as "virgin" CTCs. The reported gene expression analysis was performed for virgin CTCs (see Fig. [1](#Fig1){ref-type="fig"}). For proceeding with an in vitro culture of these cells, we analyzed the gene expression of the cells captured (or grown) on the membrane (so called membrane fraction) as well as the fraction of cells that were able to overgrow the membrane and set up a new cell culture on the bottom of the cultivation plastic (see Fig. [1](#Fig1){ref-type="fig"}, "bottom fraction"). The gene expression of the tumor-associated markers in the CTC-enriched fractions was then compared with the gene expression of these markers in the whole blood RNA.Fig. 1Gene expression analysis of the enriched CTC-fractions

Cytomorphological analysis {#Sec5}
--------------------------

Stained membranes were examined using light microscopy in two steps: (1) screening at ×20 magnification to locate cells; (2) observation at ×40--×60 magnification for detailed cytomorphological analysis. Isolated cells and/or clusters of cells of interest (whether immunostained or not) were selected, digitized, and examined by an experienced researcher and/or pathologist. CTCs were defined as cells presenting all the following criteria: (1) nuclear size ≥10 μm); (2) irregular nuclear contour; (3) presence of visible cytoplasm; (4) high nucleus-to-cytoplasm ratio; (5) prominent nucleoli; (6) proliferation activity; (7) formation of 3D cell layers.

Gene expression analysis {#Sec6}
------------------------

For GC patients where CTC-presence was confirmed cytomorphologically (n = 10), gene expression analysis was subsequently performed. Gene expression analysis is best done in parallel with immunohistochemistry, in order to provide evidence of the epithelial origin of the captured CTCs. Gene expression of tumor associated genes (Cytokeratin-18, Cytokeratin-19, Cytokeratin-20, Cytokeratin-7, EPCAM, MUC1, HER2, EGFR) was tested, as was that of leukocyte markers (e.g. CD45, CD68), with endogenous control provided by the beta-actin gene. The gene expression of the CTCs captured on the membrane is compared to the gene expression of the tumor markers in the whole blood and between the "membrane fraction" and "bottom fraction" (see Fig. [1](#Fig1){ref-type="fig"}). The cells on the membrane were lysed by RLT-buffer with β-mercaptoethanol (Qiagen---CEEMED, Praha, Czech Republic), RNA was then isolated using RNeasy Mini Kit (Qiagen). The RNA from whole blood was isolated with a modified protocol. The protocol is including the erythrocyte-lysing step. The quality/concentration of RNA was measured by NanoDrop (ThermoScientific). As there are only a few hundred cells on the membrane, the median concentration of RNA was quite low (5--10 ng/μl). For cDNA production we used the High Capacity cDNA Reverse Transcription Kit (Life Technologies). For Gene expression analysis we employed Taqman chemistry including Taqman MGB---probes for all the above-mentioned genes (Life Technologies). (A list of Taqman probes we employed is given in the supplementary material.) The gene expression results report the CTC positivity in case of an increased gene expression of tumor-associated genes in CTC-fractions in comparison to the whole blood RNA.

Results {#Sec7}
=======

We report successful CTC isolation in 59 % of GC patients (n = 13/22). The CTC cell morphology and immunohistochemistry is shown in Fig. [2](#Fig2){ref-type="fig"}. The captured cells were stained positively for CK18. The CK18 molecule has generally been accepted as a marker of cancer with an epithelial origin (Fareed et al. [@CR8]). A summary of the CTC positivity statistics is given in Table [1](#Tab1){ref-type="table"}; Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}. Overall, the size-based filtration approach enabled the capture of viable CTCs. We proved the viability of the CTCs by culturing the CTC cells in vitro, and confirming with further analysis (e.g. immunohistochemical or molecular). If desired the DNA and RNA molecules may be used for further mutational and gene expression testing. We do not have a recent survival analysis of the group of patients tested, but thanks to the data obtained, we are able characterize CTC dissemination in the pre-defined patient sub-groups based on disease stage (see Fig. [3](#Fig3){ref-type="fig"}b, c). It is of interest that 70 % of patients with resectable GC were CTC-positive, while patients deemed unresectable were only 50 % positive. The CTC-positivity rates in resectable/non-resectable GC patients and other GC-subgroups were compared by Chi square testing. No significant difference was found comparing resectable and non-resectable group of patients in our study (*P* = 0.0623).Fig. 2**a** CTC with two nuclei captured and cultured on a membrane filter with visualized filter pores. **b** Nucleus counterstained with DAPI. **c** CTC captured and cultured on a membrane filter, incubated with CK-18-FITC antibody with an unspecifically visualized micronucleus, with nucleus of irregular shape counterstained with DAPIFig. 3**a** Gastric cancer disease stage and CTC--positivity ratio. **b** T stage in Gastric cancer and CTC positivity. **c** N stage in Gastric cancer and CTC positivityFig. 4Resectability of gastric cancer and CTCs positivity

Although the study group of GC patients was relatively small, the CTC-positive rates correlate with the disease stage as well as lymph node involvement. Samples from GC patients where CTC-presence was proven cytomorphologically were eligible for subsequent gene expression analysis. The gene expression results can serve as additional evidence of epithelial cell-origin alongside the immunohistochemistry. Analyzing the molecular character of the CTCs we may conclude that in our GC CTCs samples, an increased cytokeratin-18 and cytokeratin-19 expression was seen in all of the tested samples, with some redundant EpCAM and MUC1 expression as well. In none of the tested samples was cytokeratin-7 found. Gastric tumor histology confirmed the expression of HER2 and EGFR. In all the samples tested CD45 and CD68 expression was reported, but the expression level was much lower in the enriched CTC-samples on the membrane or after in vitro culture. We can report that the mRNA transcripts of cytokeratins and other possible epithelial markers are more abundant in the enriched CTC-fractions than in the whole blood. These facts combined with the cytomorphological analysis seem to be reasonable evidence for CTC-presence and successful CTC-detection. A combination of vital cell stain and subsequent gene expression analysis of the stained cells on the membrane could give an immediate answer as to what kind of the cells have been isolated.

Discussion {#Sec8}
==========

The detection of malignant cells in blood has been established for many years (Engell [@CR6]). More recent studies have demonstrated the malignant nature of CTCs (Fehm et al. [@CR9]). In the early days of CTC research several groups attempted to identify and detect CTCs in PB but only by reverse transcription polymerase chain reaction (RT-PCR). In their study Soeth et al. ([@CR21]) noted that GC patients found positive for CK 20 mRNA (17 % of 30 patients) had significantly shorter survival times than those who tested negative. Miyazono et al. ([@CR17]) examined the presence of CTCs in blood samples from 57 GC patients. After density gradient separation of CTCs, CEA-specific real-time RT-PCR was performed and correlated with the time course during the surgical procedure and the onset/advent of hepatic tumor recurrence. Interestingly, the authors were able to show that CEA-mRNA could not be detected in a control group of healthy volunteers or in 15 patients with benign disease. In contrast, a total of 21 GC patients (36.8 %) were positive for CTCs as detected by CEA-specific RT-PCR and positive rates correlated with depth of tumor invasion. In addition, the authors found that GC patients with high levels of CEA were more likely to develop systemic disease.

In our study we saw higher CTC-positive rates than previously reported. But this may be caused by the enrolling in our study of patients with more advanced stages of GC. Another possibility is that the combination of cytomorphological and molecular analysis could be more sensitive for CTC detection in GC cases than previously reported methods. The big advantage of our approach is the ability to obtain biological material, namely CTCs cells, which are suitable for further downstream molecular analysis, e.g. gene expression profiling.

With the introduction of immunomagnetic separation techniques, not only detection but also quantification of CTCs becomes possible (Allard et al. [@CR2]). Matsusaka et al. ([@CR16]) showed that the number of CTCs before and during treatment is an independent prognostic and predictive marker in GC patients. Patients with more than 4 CTCs identified at 2 and 4-weeks after start of chemotherapy had a shorter median progression-free survival (PFS), (1.4, 1.4 months, respectively) than those with \<4 CTCs (4.9, 5.0 months, respectively). Patients with more than 4 CTCs at 2 and 4-weeks after initialization of chemotherapy had shorter median overall survival (OS), (3.5, 4.0 months, respectively) than those with \<4 CTCs (11.7, 11.4 months, respectively).This study was performed using immunomagnetic platform with magnetic beads labelled with antibodies to GC cells that express specific cells surface antigens (EpCAM, CK8, CK18, CK19 and CD45). All antibody-based enrichment techniques may be limited by the possible loss of cells without the expression of epithelial antigens as metastatic cells undergo epithelial-mesenchymal transition (EMT). Changes in the cytoskeleton of epithelial cells such as the regression of cytokeratin can be observed (Sun et al. [@CR22]). Several size-based filtration devices seek to overcome this limitation of lower sensitivity of antibody methods (Zheng et al. [@CR28]). Similarly, we have shown a successful filtration-based approach for CTC detection, finding that 59 % of GC patients in the study were CTC positive.

Uenosono et al. ([@CR24]) published a study covering 251 patients with resectable and non-resectable GC (Uenosono et al. [@CR24]). CTCs were detected in 16 patients (10.8 %) of the resection group and 62 patients (60.2 %) of the non-resectable group. The OS rate for the entire cohort was significantly lower in patients with CTCs than in those without them (*P*  \<  0.0001). A significantly smaller number of patients took part in our study, but a very high proportion of our "resectable" group were CTC positive (70 %). The significant difference between Uenosono and colleague's study and ours was the CTC-detection platform. Uenosono employed an epithelial marker-dependent methodology (CellSearch^®^), whereas we used an antibody-independent technology platform (MetaCell^®^) that identifies CTCs by size. The choice of detection platform is important because of Epitelial-Mesenchymal Transduction (EMT), a widely reported prerequisite for metastasis, which may lead to underestimation of CTC numbers. The inadequacy of the EpCAM-based immunomagnetic capture method compared with the size-based filtration method has been reported in several studies for different cancers (Farace et al. [@CR7]; Krebs et al. [@CR14]).

The advantage of the filtration method that we used is not only a higher detection rate but the ability to separate viable cancer cells. Enriched viable CTCs can be cultured for downstream testing as shown by gene-expression analysis or for single-cell analysis to detect CTC heterogeneity. For the first time in the study of GC the reported platform enables separation of viable CTCs and their subsequent cultivation.
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This research was supported by the "CTC in gastrointestinal cancer" research project awarded by League against cancer, Prague and a Grant (IGA NT14439-3/2013) from the Czech Ministry of Health. And also by the projects PRVOUK P27 from Charles University in Prague.
